Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Perception of QD Dosed Kaletra (Tablets) Based Treatment in HIV Infected Patients. Observational Cross-Sectional Study (QD-KAPITAL)

NCT01383005 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01383005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01383005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Perception of QD Dosed Kaletra (Tablets) Based Treatment in HIV Infected Patients. Observational Cross-Sectional Study (QD-KAPITAL)
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Observational
Overall status
Completed
Start date
June 30, 2011
Completion date
December 31, 2011
Enrollment
97 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus infection